ORLANDO, FL, USA (UroToday.com) - Castration-resistant prostate cancer (CRPC) most commonly metastasizes to the bone. Approximately 90% of all men with metastatic CRPC harbors osseous disease. Other less common sites of metastasis include lymph nodes, liver, lung, and soft tissue, among others.
With new therapies extending survival in metastatic CRPC, we hypothesized that the incidence of non-osseous metastases is increasing over time. In this study, we evaluated the pattern of metastatic disease in CRPC as reported in baseline characteristics of prospective clinical trials over 2 decades....Click here to enlarge and view the poster
Presented by William K. Oh, MD; Stephanie M. Doctor; James Godbold, PhD; Matthew D. Galsky MD; and Che-Kai Tsao MD at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY USA